Yongbao Zhuang and Wenyang Shi: Scientific thinking with meaningful real-world impact
Doctoral researchers Yongbao Zhuang and Wenyang Shi are interns at the Medaffcon office in Stockholm.
Latest News
Follow us on LinkedIn to stay up-to-date!
Latest articles
-
-
Medaffcon Contributes to the Public Good through Academic Collaboration
While the majority of Medaffcon’s revenue comes from the pharmaceutical industry, the company’s activities are not limited only to commercial projects. At any given time, several academic projects may be ongoing.
-
A Study on Waldenström’s Macroglobulinemia Demonstrates the Concrete Potential of Registry Research
The study generated significant new insights into the epidemiology, treatment, and prognosis of the rare blood cancer Waldenström’s macroglobulinemia.
-
Digital contraception is a cost-effective alternative to hormonal contraception
Digital solutions challenge established perceptions of what constitutes acceptable contraceptive methods and which health benefits are considered measurable.
-
Hospital data enabled a comprehensive RWE study on the treatment of complex lung cancer
The RWE study examined the treatment of patients with metastatic NSCLC, illustrating how treatment practices have changed from the first years of immunotherapy to present day.
-
Finland Introduces a National Health Data Space Model – The Role of Industry Still Needs Clarification
The objective is to improve access to health data for research and innovation, but the proposal raises concerns about increased administrative burden and the role of industry within the model.
Latest in Real-World Evidence
-
Finland Introduces a National Health Data Space Model – The Role of Industry Still Needs Clarification
The objective is to improve access to health data for research and innovation, but the proposal raises concerns about increased administrative burden and the role of industry within the model.
-
Applying Transportability to Strengthen Pharma Evidence in the Nordics
Transportability and generalizability refer to the ability to apply evidence from a single study to different patient populations, clinical settings, or geographical regions.
-
The Secondary Use Act Will Be Reformed in 2026, Streamlining the Use of Data in Research
The reform of the Secondary Use Act will establish a new decentralised process, in parallel to the current centralised permit model in which Findata grants all data permits.
-
Finland Leads the Way Toward the EHDS, but Local Readiness Remains Limited
Finland is moving toward the European Health Data Space (EHDS) with strong national systems, but local readiness, funding, and interoperability remain challenges.
-
Preparing for the EHDS Era in Sweden Requires Major Investments
The European Health Data Space Regulation (EHDS) is set to transform the use of health data across Europe.
-
Up to 20–30 Percent of All Care May Be of Low Value to Patients
Eliminating low-value care is a key means of safeguarding the sustainability and quality of healthcare.
Latest in Market Access
-
Medaffcon Contributes to the Public Good through Academic Collaboration
While the majority of Medaffcon’s revenue comes from the pharmaceutical industry, the company’s activities are not limited only to commercial projects. At any given time, several academic projects may be ongoing.
-
Digital contraception is a cost-effective alternative to hormonal contraception
Digital solutions challenge established perceptions of what constitutes acceptable contraceptive methods and which health benefits are considered measurable.
-
ISPOR Nordic Chapter Brings a Nordic Voice in a Global Network
The Nordic Chapter brings together a wide range of stakeholders from across the Nordic countries, providing a platform where research, policy-making and everyday healthcare practice meet.
-
ISPOR Emphasised Concerns about Europe’s Position in Global Pharmaceutical Development
What do you remember from the ISPOR conference in November? In this overview we discuss which topics are worth following in 2026.
-
Applying Transportability to Strengthen Pharma Evidence in the Nordics
Transportability and generalizability refer to the ability to apply evidence from a single study to different patient populations, clinical settings, or geographical regions.
-
Customer Needs at the Centre of Patient Dynamics Development
Medaffcon develops the Patient Dynamics tool based on customer feedback and user experience.
Latest in Data Science
-
Applying Transportability to Strengthen Pharma Evidence in the Nordics
Transportability and generalizability refer to the ability to apply evidence from a single study to different patient populations, clinical settings, or geographical regions.
-
Target Trial Emulation brings the logic of randomized trials into real-world data
Target Trial Emulation does not replace randomized controlled trials, but it applies their logic and rigor to real-world data analysis.
-
Data Team is the Backbone of Medaffcon, Ensuring the Reliability of Research Results
The data team keeps Medaffcon's research projects on track and ensures that the research findings are scientifically sound. At the heart of the team’s work is the processing and analysis of patient data, particularly in RWE studies.
-
Medaffcon’s Machine Learning Algorithm Adapts to Various Research Needs
The algorithm was originally developed to extract smoking status from patient texts with purpose to analyze the effects of smoking on postoperative complications. Today, it is also being utilized in lung cancer research.
-
AI Brings New Opportunities to RWE Research – Its Use in Health Data Analysis is Limited
Artificial intelligence (AI) is transforming research and working life across various industries. But what is its significance in health data analysis and real-world evidence (RWE) research? Medaffcon’s experts, Juhani Aakko and Lisse-Lotte Hermansson, share their perspectives on AI in their work.
-
Finland: An Ideal Environment for the Pharmaceutical Industry’s Real-World Evidence (RWE) Studies
Finland boasts numerous strengths that make it an outstanding choice for real-world data-based (RWD) research.
Study summaries
-
A Study on Waldenström’s Macroglobulinemia Demonstrates the Concrete Potential of Registry Research
The study generated significant new insights into the epidemiology, treatment, and prognosis of the rare blood cancer Waldenström’s macroglobulinemia.
-
Hospital data enabled a comprehensive RWE study on the treatment of complex lung cancer
The RWE study examined the treatment of patients with metastatic NSCLC, illustrating how treatment practices have changed from the first years of immunotherapy to present day.
-
New Studies Confirm Urgent Need to Enhance Management of Diabetes and Diabetic Kidney Disease in Finland
The monitoring and diagnosis of diabetic kidney disease are often insufficient in Finland. This is confirmed by two real-world evidence (RWE) studies.
-
Early initiation of biologic treatment in psoriasis helps prevent the cumulative burden of disease
A large proportion of patients with psoriasis need to switch biologic treatment after initiation. This finding emerges from two RWE studies focusing on plaque psoriasis and psoriatic arthritis.
-
Medaffcon’s CORE Data Shows: Hospital Care Costs Declining, PD-L1 Testing and Immuno-Oncology Treatments Increasing in the HUS Region of Finland
The studies are based on Medaffcon’s Collaboration Research (CORE) dataset – a unique research platform.
-
Overall survival among SCT patients with multiple myeloma has improved between 2013 and 2022
This Finnish registry-based study investigated the development of treatment practices and patient outcomes between 2013 and 2022.
Most popular articles
-
Digital contraception is a cost-effective alternative to hormonal contraception
Digital solutions challenge established perceptions of what constitutes acceptable contraceptive methods and which health benefits are considered measurable.
-
The Nordics Should Collaborate in the Life Science Sector
Access times to medicines vary greatly between European countries, and delays in oncology drugs in particular are increasing.
-
Target Trial Emulation brings the logic of randomized trials into real-world data
Target Trial Emulation does not replace randomized controlled trials, but it applies their logic and rigor to real-world data analysis.
-
The Demand for Outsourced Experts is Growing in Pharmaceutical Companies
Medaffcon provides skilled temporary workforce solutions for its client companies. An outsourced expert is a flexible solution to address a company's short-term resourcing challenges.
-
Payers Expect Clearer Demonstration of Health Technology Benefits
Sweden and Finland are leaders in developing and applying health technology and provide ideal environments for conducting Health Technology Assessments (HTA) for medical devices.
-
Medaffcon’s Patient Dynamics Tool Helps Focus and Find the Right Actions
Patient Dynamics caters to the needs of pharmaceutical companies by providing precise information for sales and marketing decision-making.
-
Pharmaceutical Pricing and Market Access of Medicine Products in Finland
Medicines in Finland are divided into medicines in ambulatory and hospital care. This article describes these two routes and provides information of the market access options and pricing system in Finland. Updated annually.